Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray

Cancer Journal

Volumn 11, Issue 5, 2005, Pages 404-411

  Choi, Doo Ho ^a,b   Kim, Sung ^a,b   Rimm, David L ^a,b   Carter, Darryl ^a,b   Haffty, Bruce G ^a,b,c  

^a Yale University School of Medicine ^*

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Breast carcinoma; Tissue microarray; Young age

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE MICROARRAY;

EID: 28444471641     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200509000-00008     Document Type: Article

References (44)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Chung M, Chang HR, Bland KI et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer J Clin 2005;55:10-30.
3. Bonnier P, Romain S, Charpin C et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995;62:138-144.
4. de la Rochefordiere A, Asselain B, Campana F et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-1043.
5. Fowble BL, Schultz DJ, Overmoyer B et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994;30:23-33.
6. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337: 949-955.
7. Veronesi U, Marubini E, Del Vecchio M et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995;87: 19-27.
8. Harrold EV, Turner BC, Matloff ET et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. Cancer J Sci Am 1998;4:302-307.
9. Kurtz JM, Jacquemier J, Amalric R et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990;8:591-598.
10. Haffty BG, Fischer D, Rose M et al. Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol 1991;9: 997-1003.
11. Remvikos Y, Magdelenat H, Dutrillaux B. Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis. Breast Cancer Res Treat 1995;34:25-33.
12. Haffty BG. Molecular and genetic markers in the local-regional management of breast cancer. Semin Radiat Oncol 2002;12: 329-340.
13. Haffty BG, Fischer D, Fischer JJ. Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys 1990;19:859-865.
14. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
15. Rimm DL, Camp RL, Charette LA et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31.
16. Moch H, Kononen T, Kallioniemi OP et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001;8:14-20.
17. Torhorst J, Bucher C, Kononen J et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256.
18. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80: 1943-1949.
19. Santiago RJ, Wu L, Harris E et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 2004;58:233-240.
20. Haffty BG, Harrold E, Khan AJ et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359:1471-1477.
21. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
22. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001;19: 3817-3827.
23. Molino A, Micciolo R, Turazza M et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997;45:241-249.
24. Layfield LJ, Saria EA, Conlon DH et al. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance. J Surg Oncol 1996;61:177-184.
25. Clark GM, Wenger CR, Beardslee S et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993;71:2157-2162.
26. Lohmann C, Gibney E, Cotsonis G et al. Progesterone receptor immunohistochemical quantitation compared with cytosolic assay: correlation with prognosis in breast cancer. Appl Immunohistochem Mol Morphol 2001;9:49-53.
27. Castiglione F, Sarotto I, Fontana V et al. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer Res 1999;19:4555-4563.
28. Hellemans P, van Dam PA, Weyler J et al. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 77:354-360.
29. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-325.
30. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360
31. Silvestrini R, Benini E, Daidone MG et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-970.
32. Silvestrini R, Veneroni S, Benini E et al. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997;89:639-645.
33. Zellars RC, Hilsenbeck SG, Clark GM et al. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 2000;18:1906-1913.
34. Rosen PP, Lesser ML, Arroyo CD et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995;13:821-830.
35. Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast carcinoma. Cancer 1994;74:381-400.
36. Bagwell CB, Clark GM, Spyratos F et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry 2001;46:121-135.
37. Broet P, Romain S, Daver A et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 2001;19:2778-2787.
38. Silvestrini R. Relevance of DNA-ploidy as a prognostic instrument for solid tumors. Ann Oncol 2000;11:259-261.
39. Stal O, Dufmats M, Hatschek T et al. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993;11: 1717-1722.
40. Molino A, Micciolo R, Turazza M et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997;74: 433-437.
41. Rudolph P, Alm P, Heidebrecht HJ et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 1999;91:271-278.
42. Ioachim EE, Malamou-Mitsi V, Kamina SA et al. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res 2000;20:4221-4225.
43. Alsabeh R, Wilson CS, Ahn CW et al. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 1996;9:438-444.
44. Jones BA, Kasl SV, Howe CL et al. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2004;101:1243-1301.